Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

NCT02938273 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG: avelumab
RADIATION: radiotherapy
DRUG: cetuximab

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]